Factor I Derivatives Modulating C3b Feedback Cycle in AMD
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Age-related Macular Degeneration (AMD) is associated with overactivity of the complement C3b feedback cycle, leading to increased inflammation and tissue damage, which existing treatments have not adequately addressed.
Innovation Solution
Administration of Factor I or its derivatives with at least 90% amino acid identity, which retain C3b-inactivating and iC3b-degradation activity, to increase plasma levels beyond normal ranges, thereby modulating the complement system and reducing inflammatory responses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing treatments are used for AMD, then general complement inhibition is attempted, but the C3b feedback cycle overactivity is not adequately addressed
Solution Approach 1:
The patent changes the parameter of complement inhibition specificity by targeting Factor I to enhance C3b inactivation and iC3b degradation activities, rather than using general complement inhibition approaches. This selective parameter change addresses the specific overactivity of the C3b feedback cycle in AMD while preserving other complement functions.
Solution Approach 2:
Factor I serves as an intermediary substance that mediates the control of C3b feedback cycle overactivity. By administering Factor I or its derivatives, the patent introduces a specific mediator that enhances C3b inactivation and iC3b degradation, thereby controlling the harmful inflammatory responses without broadly suppressing the complement system.
2Reliability
If Factor I levels are increased to enhance C3b-inactivating activity, then the C3b feedback cycle is inhibited, but the complexity of the treatment increases
Solution Approach 1:
The patent uses recombinant Factor I or its derivatives as a simplified copy or analog of the natural Factor I protein. This approach simplifies the treatment by using a single, well-defined molecular entity that can be produced through recombinant DNA technology, avoiding the complexity of plasma-derived products while maintaining the necessary C3b-inactivating and iC3b-degradation activities.
3Reliability
If Factor I or derivatives are administered to increase plasma levels, then C3b-inactivating and iC3b-degradation activities are enhanced, but the manufacturing and purification processes become more complex
Solution Approach 1:
The patent replaces complex mechanical separation and purification processes with recombinant DNA technology. Instead of manually purifying Factor I from plasma through multiple separation steps, the invention uses genetic engineering to produce Factor I or its derivatives in cultured cells, which can then be purified through standardized biopharmaceutical processes. This substitution of manufacturing methodology significantly simplifies production while ensuring consistent quality and activity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The increased levels of Factor I or its derivatives effectively inhibit the C3b feedback cycle, reducing inflammation and potentially slowing the progression of AMD by enhancing C3b-inactivating and iC3b-degradation activities, thereby providing a therapeutic benefit for AMD treatment and prevention.
Implementation Method 1
Factor I or a fragment or derivative of Factor I that has at least 90% amino acid identity across the entire length of the sequence with native Factor I and that retains C3b-inactivating and iC3b-degradation activity
Implementation Method 2
Factor I or a fragment or derivative of Factor I that has at least 90% amino acid identity across the entire length of the sequence with native Factor I and that retains C3b-inactivating and iC3b-degradation activity
Data Source
Figure 1
Figure 2
Figure 3
AI summary
Raising the level of Factor I above physiological levels can be used to treat diseases in which the underlying pathology is linked to overactivity of the C3b-feedback cycle and the generation and pro-inflammatory effects of iC3b. Methods, agents, and compositions for treatment of such diseases are described.